Citations

Mayo Clinic

Showing 10 of 108522 citations.

Multi‐Functional Biomaterial for the Treatment and Prevention of Central Line‐Associated Bloodstream Infections
Keum, Hyeongseop , Albadawi, Hassan , Zhang, Zefu , Çevik, Enes , Öklü, Rahmi , Kim, Jinjoo , Graf, Erin H. , Oklu, Rahmi

Advanced Materials | August 15, 2024 | Volume: 36 | Issue: 46 | Pages: No page available

10.1002/adma.202405805 | PMID 39148150 Get It

AbstractCentral venous catheters are among the most used medical devices in hospitals today. Despite advances in modern medicine, catheter infections remain prevalent, causing significant morbidity and mortality worldwide. Here, SteriGel is reported, which is a multifunctional hydrogel engineered to prevent and treat central line‐associated bloodstream infections (CLABSI). The mechanical properties of SteriGel are optimized to ensure appropriate gelation kinetics, bio‐adhesiveness, stretchability, and recoverability to promote durability upon application and to provide persistent protection against infection. In vitro assays demonstrated that SteriGel exhibits long‐term antimicrobial efficacy and has bactericidal effects against highly resistant patient‐derived pathogens known to be frequently associated with CLABSI. SteriGel outperformed Biopatch, which is a clinically used device for CLABSI, in ex vivo cadaver studies that simulate clinical scenarios. Furthermore, SteriGel has biocompatible, pro‐healing, and anti‐inflammatory properties in vitro and in a rat subcutaneous injection model, suggesting a potential synergistic effect in the prevention and treatment of CLABSI. SteriGel is a multifunctional adherent biomaterial with potent antimicrobial effects for sustained sterility while promoting healing of the catheter incision site to protect against infection.
Percutaneous Delivery of Oncogel for Targeted Liver Tumor Ablation and Controlled Release of Therapeutics
Albadawi, Hassan , Zhang, Zefu , Keum, Hyeongseop , Çevik, Enes , Nagalo, Bolni Marius , Gündüz, Şeyda , Kita, Hirohito , Öklü, Rahmi , Oklu, Rahmi , Kita, H , Nagalo, Bolni

Advanced Materials | August 15, 2024 | Volume: 36 | Issue: 45 | Pages: No page available

10.1002/adma.202406080 | PMID 39148179 Get It

Abstract Advanced‐stage liver cancers are associated with poor prognosis and have limited treatment options, often leading the patient to hospice care. Percutaneous intratumoral injection of anticancer agents has emerged as a potential alternative to systemic therapy to overcome tumor barriers, increase bioavailability, potentiate immunotherapy, and avoid systemic toxicity, which advanced‐stage cancer patients cannot tolerate. Here, an injectable OncoGel (OG) comprising of a nanocomposite hydrogel loaded with an ionic liquid (IL) is developed for achieving a predictable and uniform tumor ablation and long‐term slow release of anticancer agents into the ablation zone. Rigorous mechanical, physiochemical, drug release, cytotoxicity experiments, and ex vivo human tissue testing identify an injectable version of the OG with bactericidal properties against highly resistant bacteria. Intratumoral injection of OG loaded with Nivolumab (Nivo) and doxorubicin (Dox) into highly malignant tumor models in mice, rats, and rabbits demonstrates enhanced survival and tumor regression associated with robust tissue ablation and drug distribution throughout the tumor. Mass cytometry and proteomic studies in a mouse model of colorectal cancer that often metastasizes to the liver indicate an enhanced anticancer immune response following the intratumoral injection of OG. OG may augment immunotherapy and potentially improve outcomes in liver cancer patients.
Impact of transcatheter edge to edge repair in functional mitral regurgitation and cardiac resynchronization‐therapy nonresponders
Abraham, Bishoy , Suppah, Mustafa , Elbanna, Mostafa , Kaldas, Sara, Fortuin, F. David , Sweeney, John , Ayoub, Chadi , Sell-Dottin, Kristen, Megaly, Michael S. , Alsidawi, Said , Alkhouli, Mohamad , Sell‐Dottin, Kristen , Chao, Chieh‐Ju , Arsanjani, Reza

Catheterization and Cardiovascular Interventions | August 15, 2024 | Volume: 104 | Issue: 4 | Pages: 829-836

10.1002/ccd.31190 | PMID 39146522 Get It

AbstractBackgroundDespite optimal medical therapy and cardiac resynchronization therapy (CRT), significant functional mitral regurgitation (MR) persisted in 30% of the patients and labeled as CRT nonresponders.AimsWe sought to study the impact of transcatheter edge‐to‐edge repair (TEER) in patients with symptomatic grade III and IV functional MR despite CRT.MethodsA retrospective analysis was conducted of all patients who had prior CRT for at least 6 months and underwent TEER for significant residual functional MR (grade ≥3) and symptomatic heart failure (HF) at our institution. The primary outcomes were the change in New York Heart Association classification (NYHA), MR grade, echo parameters, and NT‐ProBNP from baseline to 1‐year post‐procedure.ResultsA total of 28 patients were identified, mean age of 73 ± 6.7 years and 89% males. Procedure success was achieved in all patients. At 1‐year follow‐up, patients had lower MR grade (median 2, IQR 1 [1,2] vs. 4, IQR 1 [3,4]; p < 0.001), NYHA class (median 2, IQR 1 [2,3] vs. 3, IQR 1 [3,4]; p < 0.001), and NT‐ProBNP (7658 ± 11322 vs. 3760 ± 4431; p = 0.035) compared to before the TEER procedure. The left ventricular end‐diastolic volume (255 ± 59 vs. 244 ± 66 mm; p = 0.016) and the right ventricular systolic pressure (52 ± 14 mmHg vs. 37 ± 13 mmHg, <0.001) decreased.ConclusionPatients who remain symptomatic after CRT with severe functional MR had improved functional status and MR grade at 1‐year following TEER. There was a signal toward reverse remodeling.
The Use of Immunomodulators, Biologic Therapies, and Small Molecules in Patients With Inflammatory Bowel Disease and Solid Organ Transplant
Ghusn, Wissam , Mourad, Fadi H. , Francis, Fadi, Pasha, Shabana F., Pasha, Shabana, Farraye, Francis A. , Hashash, Jana G.

Journal of Clinical Gastroenterology | August 15, 2024 | Volume: 59 | Issue: 1 | Pages: 24-35

10.1097/mcg.0000000000002049 | PMID 39145836 Get It

Patients with inflammatory bowel diseases (IBDs) may require solid organ transplants (SOTs) for multiple reasons, making its prevalence slightly higher than the general population. Although immunosuppression used in SOT may help control IBD-related inflammation, many patients still require additional immunosuppressive medications. We aim to assess the effectiveness and safety of the combination of SOT-related immunosuppression and IBD medications in patients with liver, kidney, or heart transplantation. We conducted a clinical review using PubMed, Scopus, MEDLINE, Embase, and Google Scholar databases for our search. We included data from systematic reviews, meta-analyses, case series, and case reports to assess the safety, effectiveness, and side effect profile of immunomodulators, biologic therapies, and small molecules in patients with SOT. Our review encompassed 25 liver, 6 kidney, and 1 heart transplant studies involving patients with IBD. Common liver transplant immunosuppressants included tacrolimus, mycophenolate mofetil, cyclosporine, and steroids. Anti-TNF agents, widely used in all SOT types, showed no significant safety issues, though infections and malignancies were noted. Patients with liver transplant on tacrolimus responded well to anti-integrins and ustekinumab without major complications. For kidney transplants, cyclosporine and tacrolimus were prevalent, and their combination with anti-TNF or ustekinumab was generally safe, with rare reports of malignancy or infection. Hence, the use of anti-TNF, anti-integrin agents, and ustekinumab appears to be safe in patients with SOT, regardless of their transplant related immunosuppression. More studies are needed in patients with kidney and heart transplants and in patients treated with small molecules for their IBD.
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer
O’Regan, Ruth, Francis, Prudence A. , Kammler, Roswitha , Viale, Giuseppe, Dell’Orto, Patrizia , Láng, István, Bellet, Meritxell , Bonnefoi, Hervé , Villa, Federica , Bernardo, Antônio , Neven, Patrick , Müller, Bettina , Zaman, Khalil , Martino, Silvana, Jerzak, Katarzyna J. , Davidson, Nancy E. , Mackelenbergh, Marion van , Schnabel, Catherine A. , Treuner, Kai , Regan, Meredith M. , Ingle, James N. , Bonnefoi, Hervé R , Francis, Prudence A , Zhang, Yi , Fleming, Gini F. , Viale, G., Tondini, Carlo Alberto , Ciruelos, Eva , Karlsson, Per , Jochum, Wolfram , Geyer, Charles E. , Coleman, Robert E. , Loi, Sherene , Colleoni, Marco

JAMA Oncology | August 15, 2024 | Volume: 10 | Issue: 10 | Pages: 1379

10.1001/jamaoncol.2024.3044 | PMID 39145953 Get It

ImportanceAdjuvant ovarian function suppression (OFS) with oral endocrine therapy improves outcomes for premenopausal patients with hormone receptor–positive (HR+) breast cancer but adds adverse effects. A genomic biomarker for selecting patients most likely to benefit from OFS-based treatment is lacking.ObjectiveTo assess the predictive and prognostic performance of the Breast Cancer Index (BCI) for OFS benefit in premenopausal women with HR+ breast cancer.Design, Setting, and ParticipantsThis prospective-retrospective translational study used all available tumor tissue samples from female patients from the Suppression of Ovarian Function Trial (SOFT). These individuals were randomized to receive 5 years of adjuvant tamoxifen alone, tamoxifen plus OFS, or exemestane plus OFS. BCI testing was performed blinded to clinical data and outcome. The a priori hypothesis was that BCI HOXB13/IL17BR ratio (BCI[H/I])–high tumors would benefit more from OFS and high BCI portended poorer prognosis in this population. Settings spanned multiple centers internationally. Participants included premenopausal female patients with HR+ early breast cancer with specimens in the International Breast Cancer Study Group tumor repository available for RNA extraction. Data were collected from December 2003 to April 2021 and were analyzed from May 2022 to October 2022.Main Outcomes and MeasuresPrimary end points were breast cancer–free interval (BCFI) for the predictive analysis and distant recurrence-free interval (DRFI) for the prognostic analyses.ResultsTumor specimens were available for 1718 of the 3047 female patients in the SOFT intention-to-treat population. The 1687 patients (98.2%) who had specimens that yielded sufficient RNA for BCI testing represented the parent trial population. The median (IQR) follow-up time was 12 (10.5-13.4) years, and 512 patients (30.3%) were younger than 40 years. Tumors were BCI(H/I)-low for 972 patients (57.6%) and BCI(H/I)-high for 715 patients (42.4%). Patients with tumors classified as BCI(H/I)-low exhibited a 12-year absolute benefit in BCFI of 11.6% from exemestane plus OFS (hazard ratio [HR], 0.48 [95% CI, 0.33-0.71]) and an absolute benefit of 7.3% from tamoxifen plus OFS (HR, 0.69 [95% CI, 0.48-0.97]) relative to tamoxifen alone. In contrast, patients with BCI(H/I)-high tumors did not benefit from either exemestane plus OFS (absolute benefit, −0.4%; HR, 1.03 [95% CI, 0.70-1.53]; P for interaction = .006) or tamoxifen plus OFS (absolute benefit, −1.2%; HR, 1.05 [95% CI, 0.72-1.54]; P for interaction = .11) compared with tamoxifen alone. BCI continuous index was significantly prognostic in the N0 subgroup for DRFI (n = 1110; P = .004), with 12-year DRFI of 95.9%, 90.8%, and 86.3% in BCI low-risk, intermediate-risk, and high-risk N0 cancers, respectively.Conclusions and RelevanceIn this prospective-retrospective translational study of patients enrolled in SOFT, BCI was confirmed as prognostic in premenopausal women with HR+ breast cancer. The benefit from OFS-containing adjuvant endocrine therapy was greater for patients with BCI(H/I)-low tumors than BCI(H/I)-high tumors. BCI(H/I)-low status may identify premenopausal patients who are likely to benefit from this more intensive endocrine therapy.
The authors reply:
Frazee, Erin N. , McNett, Molly , Sakhuja, Ankit , Andrews, Adair, Miano, Todd A. , Martin, Niels Douglas , Basu, Rajit K. , Ablordeppey, Enyo

Critical Care Medicine | August 15, 2024 | Volume: 52 | Issue: 9 | Pages: e486-e487

10.1097/ccm.0000000000006352 | PMID 39145713 Get It

Prediction of presence and severity of metabolic syndrome using regional body volumes measured by a multisensor white-light 3D scanner and validation using a mobile technology
Medina‐Inojosa, Betsy J. , Somers, Virend K. , Lara-Breitinger, Kyla , Johnson, Lynne A, López-Jiménez, Francisco , Medina-Inojosa, José R , Lopez-Jimenez, Francisco , Somers, Virend K. , Lara-Breitinger, Kyla M , Medina-Inojosa, Betsy , Medina‐Inojosa, José R.

European Heart Journal - Digital Health | August 15, 2024 | Volume: 5 | Issue: 5 | Pages: 582-590

10.1093/ehjdh/ztae059 | PMID 39318693 Get It

Abstract Aims To test whether an index based on the combination of demographics and body volumes obtained with a multisensor 3D body volume (3D-BV) scanner and biplane imaging using a mobile application (myBVI®) will reliably predict the severity and presence of metabolic syndrome (MS). Methods and results We enrolled 1280 consecutive subjects who completed study protocol measurements, including 3D-BV and myBVI®. Body volumes and demographics were screened using the least absolute shrinkage and selection operator to select features associated with an MS severity score and prevalence. We randomly selected 80% of the subjects to train the models, and performance was assessed in 20% of the remaining observations and externally validated on 133 volunteers who prospectively underwent myBVI® measurements. The mean ± SD age was 43.7 ± 12.2 years, 63.7% were women, body mass index (BMI) was 28.2 ± 6.2 kg/m2, and 30.2% had MS and an MS severity z-score of −0.2 ± 0.9. Features β coefficients equal to zero were removed from the model, and 14 were included in the final model and used to calculate the body volume index (BVI), demonstrating an area under the receiving operating curve (AUC) of 0.83 in the validation set. The myBVI® cohort had a mean age of 33 ± 10.3 years, 61% of whom were women, 10.5% MS, an average MS severity z-score of −0.8, and an AUC of 0.88. Conclusion The described BVI model was associated with an increased severity and prevalence of MS compared with BMI and waist-to-hip ratio. Validation of the BVI had excellent performance when using myBVI®. This model could serve as a powerful screening tool for identifying MS.
Blood–brain barrier dysfunction in aging is mediated by brain endothelial senescence
Novo, João P. , Gee, Lucy, Caetano, Carolina A., Tomé, Inês , Vilaça, Andreia , Jurk, Diana , Rosa, Susana , Ferreira, Lino , Caetano, Carolina , Jurk, Diana , Ferreira, Lino , Zglinicki, Thomas von , Moreira, Irina Sousa

Aging Cell | August 15, 2024 | Volume: 23 | Issue: 9 | Pages: No page available

10.1111/acel.14270 | PMID 39143890 Get It

AbstractBBB dysfunction during aging is characterized by an increase in its permeability and phenotypic alterations of brain endothelial cells (BECs) including dysregulation of tight junction's expression. Here we have investigated the role of BEC senescence in the dysfunction of the BBB. Our results suggest that the transition from young to aged BBB is mediated, at least in part by BEC senescence.
Poster 360: Long-Leg Lateral Monopodal Stress Radiographs for the Assessment of Anterior Tibial Translation with Anterior Cruciate Ligament Injury: A Prospective Study
Otremba, Jace R., Tollefson, Luke V. , Knowlan, Claire J., Kennedy, Nicholas I. , LaPrade, Robert F.

Orthopaedic Journal of Sports Medicine | August 15, 2024 | Volume: 12 | Issue: 7_suppl2 | Pages: No page available

10.1177/2325967124s00326 Get It

Objectives: The purpose of this study is to use standing anterior cruciate ligament (ACL) stress radiographs to evaluate how posterior tibial slope (PTS) compared to anterior tibial translation (ATT) in an injured knee. A secondary purpose was to determine how posterior tibial slope (PTS) affects ATT side-to-side difference. Our hypothesis was that anterior tibial translation would be higher in the injured knee compared to the contralateral side and posterior tibial slope will have a positive effect on anterior tibial translation. Methods: A retrospective study of ACL stress radiographs was assessed from patients with primary ACL reconstructions with no concomitant ligamentous injury between January 2023 and August 2023. Institutional Review Board approval was obtained. The bilateral radiographs were long-leg lateral “stress views” which was accomplished by monopodal weight-bearing in 20° flexion and are a part of the initial patient workup. Stress radiographs were utilized to measure the anterior tibial translation (ATT) and posterior tibial slope (PTS) for both knees. Differences in ATT between knees and the correlation between PTS and ATT was assessed via paired t-tests and regression analysis. Results: A final cohort of 39 patients were analyzed using preoperative ACL stress radiographs. The results reported a significant regression with positive correlation between posterior tibial slope (PTS) and anterior tibial translation for the injured knee using both anatomic (Figure 1, P<0.001, R 2 =0.302) and mechanical (Figure 2, P=0.038, R 2 =0.111) PTS measurements. Anatomic PTS measurements are better at predicting ATT for the injured knee compared to mechanical PTS measurements. Conclusions: The findings of this study report a significant regression with a positive correlation between posterior tibial slope (PTS) and anterior tibial translation (ATT) of the injured knee, with anatomic PTS measurements being a better predictor of ATT than mechanical PTS measurements. This indicates an important relationship between PTS and ATT with higher PTRS predicting higher ATT.
Poster 344: The New "Terrible Triad": Anterior Cruciate Ligament Reconstruction With Concurrent Meniscal Lateral Root and Medial Ramp Repairs
Shoemaker, Evan P , Tollefson, Luke V. , Kennedy, Nicholas I. , Homan, Morgan D. , Shah, Ayush , Sieffert, Kayla J., Wulf, Corey A., Bjerke, Brian, McGaver, Rebecca Stone , Larson, Christopher Michael , LaPrade, Robert F.

Orthopaedic Journal of Sports Medicine | August 15, 2024 | Volume: 12 | Issue: 7_suppl2 | Pages: No page available

10.1177/2325967124s00310 Get It

Objectives: The purpose of this paper was to compare patient reported outcomes (PROMs) between isolated anterior cruciate ligament (ACLR) and ACLR with concomitant medial meniscus ramp and lateral meniscus root repairs and compare PROMs between different medial meniscus ramp and lateral meniscus root repair techniques. Methods: All patients with isolated (ISO) ACL reconstruction or ACL reconstruction with concomitant medial meniscus ramp and lateral meniscus root repairs with a minimum 2 years of follow-up were retrospectively evaluated. Institutional review board approval was obtained for this study. A final total of 42 ISO-ACL patients were matched based upon age, sex, and body mass index to 40 in the “terrible triad” (TT) cohorts. Outcome measures were obtained from 32 patients in the ISO cohort, and 38 patients in the TT cohort. The PROMs used for this study include the International Knee Documentation Committee (IKDC) Subjective Knee, Cincinnati, Tegner, Lysholm, Veterans RAND 12-Item Health Survey (VR-12), and Knee Injury and Osteoarthritis Outcomes Score (KOOS) questionnaire forms. T tests and chi-square goodness of fit tests were used to compare the above PROMs both pre- and postoperatively within each cohort, and between cohorts and rates of revision or reoperation. Results: The preoperative and postoperative PROMs between patients in the isolated cohort and the triad cohort demonstrated no significant differences, except for the Physical category of the VR-12, in which the triad cohort had significantly higher results (p = 0.04) (Figure 1). Both the isolated cohort and the triad cohort reported significant differences between pre- and postoperative PROMs within their own cohorts. When comparing methods of surgery, including all-inside vs. inside-out for the medial meniscus repairs and tunnel versus no-tunnel for the lateral meniscus root repairs, no significant differences were found between postoperative PROMs. Additionally, no significant difference was found in revision or reoperative rates between the triad and isolated cohorts (p = 0.374) (Figure 2), the all-inside versus inside-out medial meniscus cohorts (p = 0.267), or the tunnel vs. no-tunnel lateral meniscus cohorts (p = 0.781). Conclusions: There was no significant difference in PROMs between isolated ACLR versus ACLR with concomitant medial meniscus ramp and lateral meniscus root repairs. While the complexity of the TT ACLR patients was more involved, PROMs and healing rates were similar and performing concurrent medial ramp and lateral root repairs at the time of ACLR should be considered.